Iphayini Lolwandle

-Delile

• Kungenzeka kusebenze ...
• Kungenzeka kungasebenzi ku ...
• Ubufakazi obanele bokukala ukusebenza kwe ...
• Ukuqapha okukhethekile nezixwayiso:

Izihlahla zikaphayini zasolwandle zikhula emazweni oLwandle iMedithera. Amagxolo asetshenziselwa ukwenza umuthi. Izihlahla zikaphayini zasolwandle ezikhula endaweni eseningizimu-ntshonalanga yeFrance zisetshenziselwa ukwenza iPycnogenol, igama lokuhweba elibhalisiwe lase-US lokukhipha okholwayo olwandle olutholakala ngokuthengisa olwandle.

Ukukhishwa kwe-maritime pine bark kusetshenziselwa i-asthma, ukwenza ngcono ukusebenza kwezemidlalo, ukusakazeka kahle okungadala imilenze ukuba ivuvuke (ukungapheli kahle kwe-venous noma i-CVI), nezinye izimo eziningi, kepha kukhona ubufakazi obuncane besayensi bokusekela okunye kwalokhu kusetshenziswa.

Imibhalo Yemvelo Yemininingwane Ephelele ukukala ukusebenza ngokuncike ebufakazini besayensi ngokwesilinganiso esilandelayo: Okusebenzayo, Okungenzeka Kusebenze, Okungenzeka Kusebenze, Okungenzeka Kungasebenzi, Cishe Okungaphumeleli, Ukungasebenzi, Nobufakazi Obunganele Bokulinganisa.

Izilinganiso zokusebenza ze Iphayini LASEMARITIME zimi kanje:

Kungenzeka kusebenze ...

• Isifuba Somoya. Ukuthatha ukukhishwa okulinganiselwe kwamagxolo ophayini wasolwandle nsuku zonke, kanye nemithi ye-asthma, kubonakala kunciphisa izimpawu ze-asthma kanye nesidingo sokuhlenga ama-inhalers ezinganeni nakubantu abadala abane-asthma. Khumbula ukuthi ukukhishwa kwamagxolo ompayini wasolwandle akufanele kusetshenziswe esikhundleni semithi yesifuba somoya.
• Ukusebenza kwezemidlalo. Abantu abasha (abaneminyaka engama-20 kuya kwengama-35) babonakala bekwazi ukuzivocavoca endaweni yokunyathela isikhathi eside ngemuva kokuthatha igxolo elilinganiselwe likakhokho wasolwandle nsuku zonke isikhathi esingangenyanga. Futhi, abagijimi abaqeqeshelwa ukuvivinya umzimba noma i-triathlon kubonakala sengathi benza kangcono ezivivinyweni nasemincintiswaneni lapho bethatha lokhu kukhishwa nsuku zonke amasonto ayi-8 ngenkathi beziqeqesha.
• Ukusakazeka okungalungile okungadala ukuthi imilenze ivuvukale (ukungapheli kahle kwe-venous noma i-CVI). Ukuthatha ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle ngomlomo kubonakala kunciphisa ubuhlungu bomlenze nobunzima, kanye nokugcinwa koketshezi, kubantu abanezinkinga zokujikeleza kwegazi. Sebenzisa lokhu kukhishwa ngamasheya okucindezela kubonakala kusebenza kakhulu kunokusebenzisa amasokisi aminyene wedwa. Abanye abantu basebenzisa i-horse chestnut seed extract ukwelapha lesi simo, kepha ukusebenzisa ukukhishwa kwegxolo likaphayini lwasolwandle kubonakala kusebenza kakhulu.

Kungenzeka kungasebenzi ku ...

• I-cholesterol ephezulu. Ubufakazi obuningi bukhombisa ukuthi ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle akwehlisi i- "cholesterol embi" (i-low-density lipoprotein (LDL) cholesterol) kubantu abane-cholesterol ephezulu.

Ubufakazi obanele bokukala ukusebenza kwe ...

• Nciphisa amakhono wokukhumbula nokucabanga okwenzeka ngokujwayelekile ngobudala. Ucwaningo oluningi kubantu asebekhulile abaphilile alutholanga inzuzo yememori noma yokucabanga ngemuva kokuthatha ukukhishwa okumisiwe kwegxolo laphayini lasolwandle.
• Ukuqina kwemithambo yegazi (i-atherosclerosis). Kunobunye ubufakazi bokuthi ukuthatha ukhonkolo olulinganiselwe lwamagxolo ompayini wasolwandle kathathu nsuku zonke amasonto ama-4 kungasiza ekuthuthukiseni ezinye zezinkinga ezibangelwa ukuqina kwemithambo.
• Ukunakwa kokushoda-i-hyperactivity disorder (ADHD). Ukuthatha ukukhishwa okumisiwe kwegxolo likaphayini lasolwandle ngomlomo akubonakali kusiza izimpawu ze-ADHD kubantu abadala. Kodwa-ke, ukuyithatha ngomlomo inyanga eyodwa kubonakala kuthuthukisa izimpawu ezinganeni.
• Isifo esingajwayelekile esifaka izilonda ezinzima emlonyeni nakwezinye izingxenye zomzimba (Behcet syndrome). Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha isicucu esimisiwe segxolo likaphayini wasolwandle kuthuthukisa izimpawu kubantu abane-Behcet syndrome.
• I-prostate ekhulisiwe (i-benign prostatic hyperplasia noma i-BPH). Ucwaningo lwakuqala luthole ukuthi ukuthatha isicucu esimisiwe segxolo likaphayini wasolwandle kuxhumene namandla angcono okuchama kubantu abane-BPH.
• Amakhono wokukhumbula nokucabanga (umsebenzi wokuqonda). Ucwaningo lwakuqala lwathola ukuthi ukuthatha ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle ngomlomo kuthuthukisa ukusebenza kwengqondo nokukhumbula kubantu abadala. Kubukeka sengathi kuthuthukisa kancane izikolo zokuhlolwa kubafundi basekolishi.
• Nciphisa amakhono okukhumbula nawokucabanga kubantu asebekhulile okungaphezu kokujwayelekile ngeminyaka yabo. Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha ukukhishwa okulinganiselwe kwegxolo likaphayini wasolwandle kuthuthukisa ukusebenza kwengqondo kubantu abadala abanokukhubazeka kwengqondo okuncane.
• Umkhuhlane ovamile. Ucwaningo lwakuqala lwathola ukuthi ukuthatha ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle ngomlomo kabili nsuku zonke ukuqala ekuqaleni komkhuhlane kubonakala kunciphisa inani lezinsuku ngomkhuhlane futhi. Futhi kunganciphisa inani lemikhiqizo ebandayo engaphezulu kwamanani edingekayo ukuphatha izimpawu.
• Uqwembe lwamazinyo. Ucwaningo lwakuqala luphakamisa ukuthi ukuhlafuna okungenani izingcezu eziyisithupha zezinsini ngokukhishwa okungeziwe kusuka kugxolo lwasolwandle lukaphayini izinsuku eziyi-14 kunciphisa ukopha futhi kuvimbele uqweqwe olwandayo.
• Isifo sikashukela. Ubufakazi bokuqala bukhombisa ukuthi ukuthatha ukukhishwa okulinganiselwe kwegxolo likaphayini wasolwandle nsuku zonke amasonto ama-3 kuya ku-12 kunciphisa ushukela wegazi kubantu abanesifo sikashukela.
• Izilonda ezinyaweni kubantu abanesifo sikashukela. Ucwaningo lwakuqala luphakamisa ukuthi ukuthatha amagxolo ophayini wasolwandle kukhishwe ngomlomo bese uwasebenzisa esikhumbeni kusiza ukupholisa izilonda ezinyaweni ezihlobene nesifo sikashukela.
• Isifo semithambo yegazi emincane kubantu abanesifo sikashukela (i-microangiopathy yesifo sikashukela). Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha amagxolo ompayini asolwandle afanayo kukhishwa kathathu nsuku zonke amasonto ama-4 kuthuthukisa ukujikeleza nezimpawu kubantu abanesifo sikashukela.
• Izinkinga zombono kubantu abanesifo sikashukela (i-retinopathy yesifo sikashukela). Ukuthatha ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle ngomlomo izinyanga ezimbili kubonakala kubambezela noma kuvimbela ukuqhubekela phambili kwesifo se-retinal esibangelwa yisifo sikashukela, i-atherosclerosis, noma ezinye izifo. Kubukeka sengathi kuthuthukisa nokubona.
• Umlomo owomile. Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle kanye namathe okufakelwa kuthuthukisa ukoma komlomo kangcono kunamathe okufakelwa wedwa.
• Ukungasebenzi kwe-Erectile (ED). Ucwaningo lwakuqala luphakamisa ukuthi ukukhishwa okulinganiselwe kwe-maritime pine bark, okusetshenziswe yedwa noma kuhlanganiswe ne-L-arginine, kungahle kuthuthukise ukusebenza kocansi emadodeni ane-ED. Kubukeka sengathi kuthatha izinyanga ezi-3 zokwelashwa ukwenza ngcono okukhulu.
• Imfiva ethimulisayo. Olunye ucwaningo lukhombisa ukuthi ukuthatha ukukhishwa okulinganiselayo kwegxolo likaphayini wasolwandle ngaphambi kokuqala kwenkathi yokungezwani komzimba kunciphisa izimpawu zokungezwani komzimba nabantu abanezifo ze-birch.
• Ama-hemorrhoids. Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle ngomlomo, kukodwa noma kuhlanganiswe nokhilimu oqukethe le nto efanayo, kuthuthukisa izinga lempilo nezimpawu zama-hemorrhoids. Olunye ucwaningo lukhombisa ukuthi ukuthatha le nto ekhishwe ngomlomo kungathuthukisa izimpawu zama-hemorrhoids kwabesifazane ngemuva kokubeletha.
• Umfutho wegazi ophezulu. Olunye ucwaningo lukhombisa ukuthi ukuthatha ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle kunganciphisa umfutho wegazi. Kepha olunye ucwaningo alukhombisanga mphumela.
• Ukuphazamiseka kwesikhathi eside kwamathumbu amakhulu okubangela ubuhlungu besisu (i-irritable bowel syndrome noma i-IBS). Ucwaningo lokuqala lwathola ukuthi ukuthatha ukukhishwa okulinganiselwe kwegxolo laphayini lolwandle kunganciphisa ubuhlungu besisu, amajaqamba nokusetshenziswa kwemithi kubantu abane-IBS.
• I-jet lag. Ucwaningo lwakuqala luthole ukuthi ukuthatha ukukhishwa okulinganiselwe kwegxolo likaphayini wasolwandle, ukuqala ezinsukwini ezingama-2-3 ngaphambi kokundiza kwendiza, kunganciphisa isikhathi lapho kuvela khona izimpawu ze-jet lag futhi kunciphise nezimpawu ze-jet lag.
• Amajaqamba omlenze. Kunobunye ubufakazi bokuthi ukuthatha ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle ngomlomo nsuku zonke kungahle kunciphise amajaqamba emilenze.
• Ukuphazamiseka kwendlebe kwangaphakathi okumakwe yisiyezi, ukulahlekelwa ukuzwa, nokukhala endlebeni (Isifo seMeniere). Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle kunganciphisa ukukhala ezindlebeni nasezimpawu jikelele kubantu abadala abanesifo sikaMeniere.
• Izimpawu zokunqamuka kokuya esikhathini. Ucwaningo lwakuqala lwathola ukuthi ukuthatha ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle ngomlomo kunciphisa izimpawu zokuya esikhathini, kufaka phakathi ukukhathala, ikhanda elibuhlungu, ukudangala nokukhathazeka, nokukhanya okushisayo.
• Ukuqoqwa kwezimpawu ezandisa ubungozi besifo sikashukela, isifo senhliziyo, nesifo sohlangothi (isifo se-metabolic syndrome). Ucwaningo lwakuqala luphakamisa ukuthi ukuthatha ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle ngomlomo kathathu nsuku zonke izinyanga eziyisithupha kwehlisa ama-triglycerides, amazinga kashukela egazini, nomfutho wegazi, futhi kwenyusa i-cholesterol ephakeme kakhulu ("enhle" noma i-HDL) kubantu abane-metabolic syndrome .
• Ukuvuvukala (ukuvuvukala) nezilonda ngaphakathi komlomo (i-oral mucositis). Ukufaka isicelo sesixazululo esiqukethe ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle ngaphakathi emlonyeni isonto elilodwa kubonakala kusiza ukwelapha izilonda zomlomo ezinganeni nasebusheni abelashwa ngemithi yokwelashwa ngamakhemikhali.
• I-osteoarthritis. Kunobufakazi obuhlanganisiwe ngokusebenza kukaphayini wasolwandle we-osteoarthritis. Ukuthatha ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle ngomlomo kunganciphisa izimpawu zizonke, kepha akubonakali kunciphisa ubuhlungu noma kuthuthukisa ikhono lokwenza imisebenzi yansuku zonke. Ucwaningo lwangaphambilini luye lwathola nokuthi ukusebenzisa ama-patches akhishwe ngokulinganayo amagxolo asolwandle opayini esikhunjeni kunganciphisa ubuhlungu kubantu abane-osteoarthritis yamadolo.
• Isifo se-Parkinson. Ucwaningo lwakuqala luthole ukuthi ukuthatha isicucu esimisiwe segxolo likaphayini wasolwandle kanye nokwelashwa kwe-levodopa / carbidopa kuthuthukisa ukuzamazama nezinye izimpawu zomzimba. Kubukeka futhi kuthuthukisa ukusebenza kwengqondo.
• Ubuhlungu kwabesifazane abakhulelwe. Ucwaningo lwakuqala luphakamisa ukuthi ukuthatha ukukhishwa okumisiwe kukaphayini wasolwandle ngomlomo nsuku zonke phakathi nezinyanga ezi-3 ezedlule zokukhulelwa kunciphisa ubuhlungu obuphansi beqolo, ubuhlungu bejoyini le-hip, ubuhlungu be-pelvic, nobuhlungu ngenxa yemithambo ye-varicose noma amajaqamba amathole.
• Ubuhlungu be-pelvic kwabesifazane. Kunobufakazi bokuqala bokuthi ukuthatha ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle ngomlomo kungasiza ekunciphiseni ubuhlungu be-pelvic kwabesifazane abane-endometriosis noma amajaqamba amakhulu okuya esikhathini.
• Isikhumba, isikhumba esilumayo (psoriasis). Ucwaningo lwakuqala lwathola ukuthi ukuthatha ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle ngomlomo kunganciphisa ubukhulu bezingqimba zesikhumba, kuthuthukise ikhwalithi yempilo, futhi kunciphise ukusetshenziswa kwe-steroids kubantu abane-psoriasis.
• Impendulo ebuhlungu emakhazeni ikakhulukazi eminwe nasezinzwaneni (iRaynaud syndrome). Ucwaningo lwakuqala lwathola ukuthi ukuthatha ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle kungathuthukisa ukubanda nobuhlungu eminweni kubantu abakulesi simo.
• Ukulahleka kwemisipha okuhlobene nobudala (sarcopenia). Ucwaningo lwakuqala lwathola ukuthi ukuthatha ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle ngomlomo kuthuthukisa ukusebenza kwemisipha kubantu abadala asebekhulile abanezimpawu zokulahleka kwemisipha.
• Isifo sokuzilimaza lapho kulimale izindlala ezikhiqiza izinyembezi namathe (iSjogren syndrome). Ucwaningo lwakuqala kubantu abane-Sjogren syndrome luthole ukuthi ukuthatha ukukhishwa okulinganiselwe kwamagxolo ompayini wasolwandle ngomlomo kunciphisa izimpawu zamehlo omile nomlomo owomile. Kunganciphisa nesidingo semithi ethile.
• Isifo esizimele esibangela ukuvuvukala okubanzi (systemic lupus erythematosus noma i-SLE). Ucwaningo lwakuqala luphakamisa ukuthi ukuthatha ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle ngomlomo kunciphisa izimpawu ze-SLE kwezinye iziguli.
• Ukukhala ezindlebeni (tinnitus). Ucwaningo lwakuqala luphakamisa ukuthi ukuthatha ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle kunciphisa ukukhala ezindlebeni.
• Imithambo ye-Varicose. Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha ukhonkolo olufanayo lwamagxolo ophayini wasolwandle kunganciphisa amajaqamba emilenze, ukuvuvukala kwemilenze, kanye nenani lemithambo ye-varicose kanye nemithambo yesicabucabu kwabesifazane ngemuva kokubeletha.
• Amahlule egazi akha emithanjeni (venous thromboembolism noma i-VTE). Ukuthatha ukhonkolo oluthile lwasolwandle lukakhayini lodwa ngaphambi nangemva kokundiza okude akubonakali kuvimbela amahlule egazi kubantu abasengozini enkulu. Kepha kunganciphisa ubungozi be-post-thrombotic syndrome. Lesi simo singakhula kubantu asebevele benegazi.
• Ukwehluleka kwenhliziyo.
• Ubuhlungu bemisipha.
• Izinkinga ngomsebenzi wezocansi.
• Ukuvimbela unhlangothi.
• Ezinye izimo.

Kudingeka ubufakazi obengeziwe ukukala uphayini wasolwandle ngalokhu kusetshenziswa.

Uphayini wasolwandle uqukethe izinto ezingathuthukisa ukugeleza kwegazi. Kungashukumisa futhi amasosha omzimba, kunciphise ukuvuvukala, kuvimbele izifo, futhi kube nemiphumela yokulwa namagciwane.

Lapho ithathwa ngomlomo: Ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle (iPycnogenol, Horphag Research) kuyinto OKUNGENZEKA UKUPHEPHA ngemithamo ye-50-450 mg nsuku zonke kuze kube unyaka owodwa. Kungadala isiyezi, izinkinga zesisu, ikhanda elibuhlungu, izilonda zomlomo nokuphefumula kabi.

Lapho isetshenziswa esikhunjeni: Ukukhishwa okumisiwe kwegxolo likaphayini wasolwandle (iPycnogenol, Horphag Research) kuyinto OKUNGENZEKA UKUPHEPHA njengokhilimu kuze kube yizinsuku eziyi-7 noma njengempuphu kuze kube amasonto ayisithupha.

Ukuqapha okukhethekile nezixwayiso:

Ukukhulelwa nokuncelisa ibele: Ucwaningo lwakuqala luphakamisa ukuthi ukukhishwa okulinganiselayo kwegxolo likaphayini wasolwandle (Pycnogenol, Horphag Research) OKUNGENZEKA UKUPHEPHA lapho isetshenziselwa ukukhulelwa sekwedlule isikhathi. Kodwa-ke, kuze kube yilapho kwaziwa okuningi, kufanele isetshenziswe ngokuqapha noma ngokugwema abesifazane abakhulelwe.

Akukho lwazi olwanele ngokwanele mayelana nokuphepha kokuthatha imikhiqizo yaphayini yasolwandle uma uncelisa ibele. Hlala ohlangothini oluphephile futhi ugweme ukusetshenziswa.

Izingane: Ukukhishwa okulinganiselwe kwegxolo likaphayini wasolwandle (iPycnogenol, Horphag Research) kuyinto OKUNGENZEKA UKUPHEPHA lapho kuthathwa ngomlomo, isikhathi esifushane.

"Izifo zokuzivikela ngokuzenzakalela" njenge-multiple sclerosis (MS), lupus (systemic lupus erythematosus, SLE), isifo samathambo (RA), noma ezinye izimo: Imayini yasolwandle ingadala ukuthi amasosha omzimba asebenze kakhudlwana, futhi lokhu kungakhuphula izimpawu zezifo zokuzivikela komzimba. Uma unesinye salezi zimo, kungcono ukugwema ukusebenzisa uphayini wasolwandle ..

Izimo zokopha: Ngokombono, amanani aphezulu opayini basolwandle angakhuphula ubungozi bokuphuma kwegazi kubantu abanezimo zokopha.

Isifo sikashukela: Ngokombono, amanani aphakeme ophayini wasolwandle anganciphisa ushukela wegazi kakhulu kubantu abanesifo sikashukela.

Isibindi: Ngokombono, ukuthatha i-maritime pine kungadala ukusebenza kwesibindi kubantu abane-hepatitis.

Ukuhlinzwa: Uphayini wasolwandle unganciphisa ukujiya kwegazi futhi wehlise ushukela wegazi. Kunokukhathazeka okuthile kokuthi kungadala ukuthi ushukela wegazi wehle kakhulu futhi kwandise ithuba lokopha ngesikhathi nangemva kokuhlinzwa. Yeka ukusebenzisa uphayini wasolwandle okungenani amasonto ama-2 ngaphambi kokuhlinzwa okuhleliwe.

Maphakathi

Qaphela ngale nhlanganisela.

Imithi yesifo sikashukela (Imithi elwa nesifo sikashukela)

Uphayini wasolwandle unganciphisa amazinga kashukela egazini. Imithi yesifo sikashukela nayo isetshenziselwa ukwehlisa ushukela egazini. Ukuthatha uphayini wasolwandle kanye nemithi yesifo sikashukela kungadala ukuthi ushukela wegazi lakho ube phansi kakhulu. Bheka ushukela wegazi lakho eduze. Umthamo wemithi yakho yesifo sikashukela ungadinga ukuguqulwa.

Eminye imithi esetshenziselwa isifo sikashukela ifaka i-glimepiride (Amaryl), i-glyburide (i-DiaBeta, i-Glynase PresTab, i-Micronase), i-insulin, i-pioglitazone (i-Actos), i-rosiglitazone (i-Avandia), neminye. Indlela yokusebenza ayikacaci.

Imithi eyehlisa amasosha omzimba (ama-Immunosuppressants)

Uphayini wasolwandle ubonakala ukwandisa amasosha omzimba. Ngokwandisa amasosha omzimba, uphayini wasolwandle unganciphisa ukusebenza kwemithi eyehlisa amasosha omzimba.

Eminye imishanguzo eyehlisa amasosha omzimba ifaka i-azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3 (OKT3, Orthoclone OKT3), mycophenolate (CellCept), tacrolimus (FK506, Prograf ), sirolimus (Rapamune), prednisone (Deltasone, Orasone), corticosteroids (glucocorticoids), nabanye.

Imithi eyehlisa ukunqamuka kwegazi (Anticoagulant / Antiplatelet drug)

Uphayini wasolwandle unganciphisa ukujiya kwegazi. Ukuthatha uphayini wasolwandle kanye nemithi nayo ejija kancane ukuvimba kungandisa amathuba okulimala nokopha.

Eminye imithi eyehlisa ijubane ukuvala igazi ifaka i-aspirin, i-clopidogrel (i-Plavix), i-dalteparin (i-Fragmin), i-enoxaparin (i-Lovenox), i-heparin, i-ticlopidine (i-Ticlid), i-warfarin (i-Coumadin) neminye.

Amakhambi nezithasiselo ezingehlisa ushukela egazini

Uphayini wasolwandle unganciphisa amazinga kashukela egazini. Ukuyisebenzisa namanye amakhambi noma izithasiselo ezinomphumela ofanayo kungadala ukuthi amazinga kashukela egazi ehle kakhulu. Amanye amakhambi nezengezo ezinganciphisa ushukela wegazi zifaka i-alpha-lipoic acid, i-chromium, i-devil's claw, i-fenugreek, i-garlic, i-guar gum, i-chestnut yamahhashi, i-Panax ginseng, i-psyllium, i-ginseng yaseSiberia, nezinye.

Amakhambi nezengezo ezinganciphisa ukujiya kwegazi

Ukusebenzisa uphayini wasolwandle kanye namakhambi anciphisa ukujiya kwegazi kungakhuphula ubungozi bokuphuma kwegazi kwabanye abantu. Lawa makhambi afaka i-angelica, i-clove, i-danshen, i-garlic, i-ginger, i-ginkgo, i-Panax ginseng, namanye.

Akukho ukuxhumana okwaziwayo nokudla.

Imithamo elandelayo ifundwe ocwaningweni lwesayensi:

ABADALA

NGOMLOMO:

• Isifuba SomoyaI-1 mg yesikhonkwane sasolwandle esisezingeni elilinganiselwe elikhishwa ngamakhilogremu wesisindo somzimba, kuze kufike ku-200 mg / ngosuku, sinikezwe ngemithamo emibili ehlukanisiwe inyanga eyodwa. Futhi, i-50 mg yokukhishwa okufanayo isetshenziswe kabili nsuku zonke izinyanga ze-6.
• Ukusebenza kwezemidlalo: 100-200 mg ukukhishwa okulinganiselwe kolwandle lukaphayini kusetshenziswe nsuku zonke izinyanga eziyi-1-2.
• Ukusakazeka okungalungile okungadala ukuthi imilenze ivuvukale (ukungapheli kahle kwe-venous noma i-CVI): I-45-360 mg yokukhishwa okulinganiselwe kolwandle lukaphayini kuthathwe nsuku zonke ngamanani amathathu ahlukanisiwe amasonto ama-3 kuya ku-12.

IZINGANE

NGOMLOMO:

• Isifuba SomoyaI-1 mg yesikhonkwane esilinganiselwe sikaphayini wasolwandle esikhishwe ngekhilogremu lesisindo somzimba sithathiwe ngemithamo emibili ehlukanisiwe izinyanga ezi-3 yizingane nentsha eneminyaka eyi-6-18.

Ama-Tannins ane-Condensed, i-orcorce de Pin, i-orcorce de Pin Maritime, i-Extrait d'Écorce de Pin, i-French Marine Pine Bark Extract, i-French Maritime Pine Bark Extract, i-Leucoanthocyanidins, i-Maritime Bark Extract, i-Oligomères de Procyanidine, i-Oligomères Procyaniderics, Oligomères Procyanidoli, Oligomères Procyanidoli , PCO, PCOs, Pine Bark, Pine Bark Extract, Pinus pinaster, Pinus maritima, Proanthocyanidines Oligomériques, Procyanidin Oligomers, Procyanodolic Oligomers, Pycnogenol, Pycnogénol, Pygenol, Tannins Condensés.

Ukuze ufunde kabanzi ngokuthi le ndatshana ibhalwe kanjani, sicela ubheke ifayela le- Imibhalo Yemvelo Yemininingwane Ephelele indlela.

1. I-Aldret RL, iBellar D. Isifundo Esingaboni Ngamehlo, Esinqamulelayo Ukuhlola Imiphumela Yokukhishwa Kwezimayini Zolwandle Ekusebenzeni Kokuzivocavoca kanye Nokuvuvukala Kokuzivocavoca, Ukuxineka Kwe-Oxidative, Imisipha Ukukhathazeka, Nokulimala. J Ukudla Suppl. 2020; 17: 309-20. Buka okungaqondakali.
2. UCesarone MR, Belcaro G, Agus GB, et al. Ukungazinzi kahle kwama-venous kanye ne-veni microangiopathy: ukuphathwa nge-compression ne-Pycnogenol®. IMinerva Cardioangiol. 2019; 67: 280-7. Buka okungaqondakali.
3. U-Hu S, uHosoi M, uBelcaro G, et al. Ukuphathwa kwe-Raynaud Syndrome emnene, eyinhloko: ukwesekwa ne-Pycnogenol®. IMinerva Cardioangiol. 2019; 67: 392-8. Buka okungaqondakali.
4. UCesarone MR, uBelcaro G, uHosoi M, et al. Ukuphathwa okungeziwe ngePycnogenol® kusifo sikaParkinson ukuvikela ukukhubazeka kwengqondo. UJ Neurosurg Sci. 2020; 64: 258-62. Buka okungaqondakali.
5. UVinciguerra G, uBelcaro G, uFeragalli B, et al. IPycnoRacer®, isiphuzo sokuzivocavoca okubandakanya iPycnogenol®, ithuthukisa ukululama nokuqeqeshwa esivivinyweni seCooper. IPanminerva Med 2019; 61: 457-63. Buka okungaqondakali.
6. UBelcaro G, uCesarone MR, uCornelli U, et al. I-Xerostomia: ukuvimbela nge-Pycnogenol® supplementation: isifundo somshayeli. IMinerva Stomatol. 2019; 68: 303-7. Buka okungaqondakali.
7. UCesarone MR, uBelcaro G, uSpipione C, et al. Ukuvimbela ukoma kwesitho sangasese sowesifazane kwabesifazane be-perimenopausal. Ukwengezwa ngeLady Prelox®. UMinerva Ginecol. 2019; 71: 434-41. Buka okungaqondakali.
8. UPourmasoumi M, Hadi A, Mohammadi H, Rouhani MH. Umphumela wesengezo se-pycnogenol ekucindezelweni kwegazi: Ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta kokuhlolwa kwemitholampilo. I-Phytother Res. 2020; 34: 67-76. Buka okungaqondakali.
9. UFogacci F, Tocci G, Sahebkar A, Presta V, Banach M, Cicero AFG. Umphumela wePycnogenol Ekucindezelweni Kwegazi: Okutholwe ku-PRISMA Compliant Systematic Review kanye ne-Meta-Analysis ye-Randomized, Double-Blind, Placebo-Controlled, Clinical Studies. I-Angiology. 2020; 71: 217-25. Buka okungaqondakali.
10. USmetanka A, uStara V, uFarsky I, uTonhajzerova I, u-Ondrejka I. Ukwengezelelwa kwePycnogenol njengokwelashwa okuhlanganisayo kokungasebenzi kahle kocansi okubangelwa ukucindezela. I-Physiol Int. 2019; 106: 59-69. Buka okungaqondakali.
11. ULuzzi R, uBelcaro G, uHu S, et al. Ukusebenza kwe-Pycnogenol supplementation ngezigaba zokuxolelwa kwe-Sjögren syndrome. IMinerva Cardioangiol. 2018; 66: 543-546. i-doi: 10.23736 / S0026-4725.18.04638-8. Buka okungaqondakali.
12. ULedda A, uBelcaro G, uFeragalli B, et al. I-Benign prostatic hypertrophy: I-Pycnogenol supplementation ithuthukisa izimpawu ze-prostate kanye nevolumu yesinye esisele. IMinerva Med. I-2018; 109: 280-284. Buka okungaqondakali.
13. U-Hu S, uBelcaro G, uLedda A, et al. I-Behçet syndrome: imiphumela ye-Pycnogenol supplementation phakathi nezigaba zokubuyela emuva. IMinerva Cardioangiol. I-2018; 66: 386-390. Buka okungaqondakali.
14. UHadi A, uPourmasoumi M, Mohammadi H, Javaheri A, uRouhani MH. Umthelela wesengezo se-pycnogenol kuma-lipids e-plasma ebantwini: Ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta kokuhlolwa kwemitholampilo. I-Phytother Res. 2019; 33: 276-287. Buka okungaqondakali.
15. UFeragalli B, uDugall M, uLuzzi R, et al. I-Pycnogenol: ukuphathwa okwengeziwe kwe-osteoarthritis enesifo esine-patch. Ucwaningo lokubhalisa lokubuka. IMinerva Endocrinol. 2019; 44: 97-101. Buka okungaqondakali.
16. UBelcaro G, uDugall M, uHu S, et al. Ukuvimbela ukuphindaphinda kwe-venous thrombosis kanye ne-post-thrombotic syndrome. IMinerva Cardioangiol. I-2018; 66: 238-245. Buka okungaqondakali.
17. Belcaro G, Cornelli U, Dugall, M, Hosoi M, Cotllese R, Feragalli B. Izindiza ezindiza isikhathi eside, i-edema, kanye nemicimbi ye-thrombotic: ukuvimbela ngamasheya kanye ne-Pycnogenol supplementation (LONFLIT Registry Study). Minverva Cardioangiologica. 2018 Ephreli; 66: 152-9. Buka okungaqondakali.
18. Ezzikouri S, Nishimura T, Kohara M, et al. Imiphumela ye-inhibitor yePycnogenol ekuphindaphindeni kwegciwane le-hepatitis C. Amagciwane Res. 2015 uJan; 113: 93-102. Buka okungaqondakali.
19. UBelcaro G, uLuzzi R, uHu S, et al. Ukuthuthuka kwezimpawu nezimpawu ezigulini ze-psoriasis ezine-Pycnogenol supplementation. IPanminerva Med. 2014 uMar; 56: 41-8. Buka okungaqondakali.
20. UBelcaro G, uGizzi G, uPellegrini L, et al. I-Pycnogenol kuma-hemorrhoids abonisa izimpawu zangemva kokubeletha. UMinerva Ginecol. 2014 Feb; 66: 77-84. Buka okungaqondakali.
21. UBelcaro G, uDugall M, uHosol M, et al. I-Pycnogenol ne-centella asiatica yokuqhubekela phambili kwe-asymptomatic atherosclerosis. Int Angiol. 2014 Feb; 33: 20-6. Buka okungaqondakali.
22. U-Ikuyama S, uFan B, uGu J, uMukae K, uWatanabe H.Molecular mechanism of intracellular lipid accumulation: suppressive effect of Pycnogenol in cell liver. Ukudla Okusebenzayo Kwezempilo Nezifo 203; 3: 353-364.
23. ULuzzi R, uBelcaro G, uHu S, et al. Ukwenza ngcono izimpawu kanye nokugeleza kwama-cochlear ne-Pycnogenol ezigulini ezinesifo sikaMeniere kanye ne-tinnitus. IMinerva Med. 2014 Juni; 105: 245-54. Buka okungaqondakali.
24. UBelcaro G, uCesarone R, uSteigerwalt J, et al. I-Jet-lag: ukuvimbela ngePycnogenol. Umbiko wokuqala: ukuhlolwa kubantu abaphilile nasezigulini ezinomfutho wegazi ophezulu. IMinerva Cardioangiol. 2008 Okthoba; 56 (5 Suppl): 3-9. Buka okungaqondakali.
25. UMatsumori A, uHiguchi H, uShimada M. Ukukhishwa kwamagxolo ophayini wasolwandle waseFrance kuvimbela ukuphindaphindeka kwegciwane futhi kuvimbele ukuthuthukiswa kwe-myocarditis yegciwane. J Card Yehluleka. 2007 uNov; 13: 785-91. Buka okungaqondakali.
26. I-Belcaro G, i-Luzzi R, i-Dugall M, i-Ippolito E, i-Saggino A. I-Pycnogenol ithuthukisa ukusebenza kwengqondo, ukunaka, ukusebenza kwengqondo kanye namakhono athile obuchwepheshe kubachwepheshe abanempilo abaneminyaka yobudala engama-35-55. UJ Neurosurg Sci. 2014 Dis; 58: 239-48. Buka okungaqondakali.
27. USarikaki V, uRallis M, Tanojo H, et al. Ukufakwa ngaphakathi kwe-vitro percutaneous kokukhishwa kwe-pine bark (Pycnogenol) esikhumbeni somuntu. UJ Toxicol 2004; 23: 149-158.
28. ULuzzi R, uBelcaro G, uHosoi M, et al. Ukujwayelekile kwezinto ezinobungozi benhliziyo nemithambo kubantu besifazane bangaphambi kokuya esikhathini nabanePycnogenol. UMinerva Ginecol. 2017 Feb; 69: 29-34. Buka okungaqondakali.
29. IValls RM, uLlaurado E, uFernandez-Castillo S, et al. Imiphumela yesisindo esiphansi samangqamuzana i-procyanidin ekhishwe ku-French maritime bark ezintweni eziyingozi yesifo senhliziyo ezigabeni-1 zezifo ezinamandla I-Phytomedicine. 2016 Nov 15; 23: 1451-61. Buka okungaqondakali.
30. Hosoi M, Belcaro G, Saggino A, Luzzi R, Dugall M, Feragalli B. Pycnogenol supplementation ekusebenzeni okuncane kokuqonda. UJ Nuerosurg Sci. 2018 Juni; 62: 279-284. Buka okungaqondakali.
31. Belcaro G, Dugall M, Ippolito E, Hus S, Saggino A, Feragalli B. Isifundo se-COFU3. Ukwenza ngcono ukusebenza kwengqondo, ukunaka, ukusebenza kwengqondo ngePycnogenol ezifundweni ezinempilo (55-70) enokuxineka okuphezulu kwe-oxidative. J Neurosurg Sci 2015 Dec; 59: 437-46.
32. UBelcaro G, uDugall M. Ukulondolozwa kwesisindo semisipha namandla ezifundweni ezindala nge-Pycnogenol supplementation. IMinerva Ortopedica e Traumatologica 2016 Septhemba; 67: 124-30.
33. UBelcaro G, uDugall M, uLuzzi R, Ippolito E, uCesarone MR. Imithambo ye-Postpartum varicose: ukwesekwa nge-pycnogenol noma ukucindezela okunwebeka-Ukulandelwa kwezinyanga eziyi-12. Int J Angiol. 2017 Mar; 26: 12-19. Buka okungaqondakali.
34. UBelcaro G, uGizzi G, uPellegrini L, et al. Ukwengezwa kwe-Pycnogenol kuthuthukisa ukulawulwa kwezimpawu zesifo samathumbu esingathukutheli. IPanminerva Med. 2018 Jun; 60: 65-89. Buka okungaqondakali.
35. I-Belcaro G. Ukuqhathaniswa komtholampilo kwe-pycnogenol, antistax, kanye nokugcina ukungasebenzi kahle okungapheli. Int J Angiol. 2015 Disemba; 24: 268-74. I-Epub 2015 Jul 15. Buka okungaqondakali.
36. Itekisi: I-Pinus pinaster Aiton. Uhlelo lwe-U.S. National Plant Germplasm. Kutholakala ku: https://npgsweb.ars-grin.gov/gringlobal/taxonomydetail.aspx?28525. Kufinyelelwe ngoMeyi 29, 2018.
37. UVinciguerra G, uBelcaro G, uBonanni E, et al. Ukuhlolwa kwemiphumela yokwenezelwa ngePycnogenol ngokuqina ezifundweni ezijwayelekile ne-Army Physical Fitness Test nasemidlalweni yabasubathi ku-triathlon yemizuzu eyi-100. J Ezemidlalo Med Fitness 2013; 53: 644-54. Buka okungaqondakali.
38. I-Sahebkar A. Ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta kwemiphumela ye-pycnogenol kuma-lipids e-plasma. UJ Cardiovasc Pharmacol Ther 2014; 19: 244-55. Buka okungaqondakali.
39. UKhurana H, Pandey RK, Saksena AK, Kumar A. Ukuhlolwa kukavithamini E kanye ne-pycnogenol ezinganeni ezine-mucositis yomlomo ngesikhathi somdlavuza womdlavuza. I-Oral Dis 2013; 19: 456-64.
40. UBottari A, uBelcaro G, uLedda A, et al. ILady Prelox ithuthukisa ukusebenza kocansi kubantu besifazane abanempilo yobudala bokuzala. UMinerva Ginecol 2013; 65: 435-44. Buka okungaqondakali.
41. UBelcaro G, Shu H, uLuzzi R, et al. Ukwenza ngcono umkhuhlane ovamile ngePycnogenol: isifundo sasebusika sokubhalisa. IPanminerva Med 2014; 56: 301-8. Buka okungaqondakali.
42. UBelcaro G, uDugall M, uLuzzi R, uHosoi M, uCorsi M.Ukuthuthukiswa kwethoni ye-venous ne-pycnogenol ekungeneni okungapheli kwama-venous: isifundo se-ex vivo ezingxenyeni ezinobuthi. I-Int J Angiol 2014; 23: 47-52. Buka okungaqondakali.
43. UBelcaro G, uCornelli U, uLuzzi R, et al. Ukwengezwa kwePycnogenol kuthuthukisa izinto ezinobungozi kwezempilo ezifundweni ezine-metabolic syndrome. I-Phytother Res 2013; 27: 1572-8. Bheka okungajwayelekile.
44. U-Asmat U, Abad K, Ismail K. Isifo sikashukela kanye nengcindezi ye-oxidative-ukubuyekeza okufingqiwe. ISaudi Pharma J 2015. Itholakala ku: http://dx.doi.org/10.1016/j.jsps.2015.03.013.
45. IMaritim AC, iSanders RA, iWatkins JB 3rd. Isifo sikashukela, ukucindezeleka okwenziwe nge-oxidative, kanye nama-antioxidants: isibuyekezo. UJ Biochem Mol Toxicol 2003; 17: 24-38. Buka okungaqondakali.
46. UFarid R, uMirfeizi Z Mirheidari M Z Rezaieyazdi Mansouri H Esmaelli H. Pycnogenol® ukwengeza kunciphisa ubuhlungu nokuqina futhi kuthuthukise ukusebenza komzimba kubantu abadala abane-osteoarthritis yamadolo. Ucwaningo Lwezokudla 2007; 27: 692-697.
47. URoseff SJ, uGulati R. Ukwenza ngcono ikhwalithi yesidoda yi-pycnogenol. I-Eur Bull Drug Res 1999; 7: 33-36.
48. UDurackova, B. Trebatický V. Novotný I. Žit®anová J. Breza. I-lipid metabolism kanye nokwenza ngcono ukusebenza kwe-Pycnogenol®, kukhishwe kumagxolo kaPinus pinaster ezigulini ezinenkinga yokungasebenzi kahle kwe-erectile - isifundo somshayeli. Ucwaningo Lwezokudla 2003; 23: 1189-1198.
49. UHosseini S, Pishnamazi S Sadrzadeh SMH Farid F Farid R Watson RR. I-Pycnogenol ekuphathweni kwesifuba somoya. J Ukudla Kwezokwelapha 2001; 4: 201-209.
50. UDurackova, Z., Trebaticky, B., Novotny, V., Zitnanova, A., noBreza, J. Lipid metabolism and erectile dysfunction improvement by Pycnogenol (R), extract from the bark of Pinus pinaster in iziguli ezine-erectile dysfunction - isifundo sokushayela indiza. Ukudla okunomsoco. 2003; 23: 1189-1198.
51. I-Kohama T, i-Negami M. Umphumela we-Low-dose French Maritime Pine Bark Extract ku-Climacteric Syndrome ku-170 Perimenopausal Women: Isivivinyo Esilawulwa Ngokungahleliwe, Esiyimpumputhe, Esilawulwa Yi-Placebo. J Zokuzala Med 2013; 58: 39-47.
52. I-Schmidtke I, iSchoop W. Pycnogenol: i-stasis edema kanye nokwelashwa kwayo. ISchweizerische Zeitschrift fur GanzheitsMedizin 1995; 3: 114-115.
53. UHosseini, S., Lee, J., Sepulveda, RT, Fagan, T., Rohdewald, P., noWatson, RR Isifundo esilawulwa ngokungahleliwe, esiyimpumputhe, esilawulwa nge-placebo, esifundweni seviki se-16 sokunquma indima yePycnogenol (R ) ekuguquleni umfutho wegazi ezigulini ezinesifo esiphakeme. Ukudla okunomsoco. 2001; 21: 67-76.
54. U-Wang S, uTan D Zhao Y et al. Umphumela we-pycnogenol ku-microcirculation, iplatelet function kanye ne-ischemic myocardium ezigulini ezinezifo zomthambo we-coronary. I-Eur Bull Drug Res 1999; 7: 19-25.
55. I-Wei, Z., Peng, Q., neLau, B. I-Pycnogenol ithuthukisa izivikelo ze-endothelial cell antioxidant. Umbiko weRedox 1997; 3: 219-224.
56. IVirgili, F., Kobuchi, H., nePacker, L.Procyanidins ekhishwe ePinus maritima (Pycnogenol): abahlaseli bezinhlobo zamahhala ezinkulu kanye nama-modulators we-nitrogen monoxide metabolism ku-activine murine RAW 264.7 macrophages. I-Radic yamahhala. Biol Med 1998; 24 (7-8): 1120-1129. Buka okungaqondakali.
57. IMacrides, T. A., Shihata, A., Kalafatis, N., neWright, P. F. Ukuqhathaniswa kwezakhiwo ze-hydroxyl radical scavenging ze-shark bile steroid 5 beta-scymnol kanye ne-pycnogenols yezitshalo. I-Biochem Mol Biol Int 1997; 42: 1249-1260. Buka okungaqondakali.
58. UNoda, Y., Anzai, K., Mori, A., Kohno, M., Shinmei, M., noPacker, L. Hydroxyl kanye ne-superoxide anion imisebenzi yokuqotha imithombo yemvelo yama-antioxidants esebenzisa uhlelo lwekhompyutha lwe-JES-FR30 ESR . I-Biochem Mol Biol Int 1997; 42: 35-44. Buka okungaqondakali.
59. UFurumura, M., Sato, N., Kusaba, N., Takagaki, K., noNayayama, J. Ukuphathwa ngomlomo kwe-French maritime pine bark extract (Flavangenol ((R))) kuthuthukisa izimpawu zomtholampilo esikhunjeni sobuso esinezithombe. Umtholampilo. Interv. Ukuguga 2012; 7: 275-286. Buka okungaqondakali.
60. UPerera, N., Liolitsa, D., Iype, S., Croxford, A., Yassin, M., Lang, P., Ukaegbu, O., neveni, u-Issum C. Phlebotonics wama-haemorrhoids. Idatha yedatha yeCochrane. 2012; 8: CD004322. Buka okungaqondakali.
61. USchoonees, A., Visser, J., Musekiwa, A., noVolmink, J. Pycnogenol (R) (kukhishwe amagxolo ophayini wasolwandle waseFrance) ekwelapheni izifo ezingalapheki. Idatha yedatha yeCochrane. 2012; 4: CD008294. Buka okungaqondakali.
62. USchoonees, A., Visser, J., Musekiwa, A., noVolmink, J. Pycnogenol ((R)) ekwelapheni izifo ezingalapheki. Idatha yedatha yeCochrane. 2012; 2: CD008294. Buka okungaqondakali.
63. UMarini, A., Grether-Beck, S., Jaenicke, T., Weber, M., Burki, C., Formann, P., Brenden, H., Schonlau, F., noKrusmann, J. Pycnogenol (R ) imiphumela ekuqineni kwesikhumba naku-hydration kuhambisana nokwanda kwezinhlobo zofuzo zohlobo lwe-collagen I kanye ne-hyaluronic acid synthase kwabesifazane. Isikhumba Pharmacol. Physiol 2012; 25: 86-92. Buka okungaqondakali.
64. UMach, J., Midgley, A. W., Dank, S., Grant, R. S., noBentley, D. J. Umphumela we-antioxidant supplementation ekukhathaleni ngesikhathi sokuzivocavoca: indima engaba khona ye-NAD + (H). Izakhamzimba. 2010; 2: 319-329. Buka okungaqondakali.
65. U-Enseleit, F., Sudano, I., Periat, D., Winnik, S., Wolfrum, M., Flammer, AJ, Frohlich, GM, Kaiser, P., Hirt, A., Haile, SR, Krasniqi, N ., Matter, CM, Uhlenhut, K., Hogger, P., Neidhart, M., Luscher, TF, Ruschitzka, F., noNoll, G. Imiphumela yePycnogenol ekusebenzeni kokuphela kweziguli ezinezifo zomthambo we-coronary ezinzile: kabili-blind, randomized, placebo-controlled, cross-over Study. Inhliziyo J. 2012; 33: 1589-1597. Buka okungaqondakali.
66. ULuzzi, R., Belcaro, G., Zulli, C., Cesarone, MR, Cornelli, U., Dugall, M., Hosoi, M., noFeragalli, B. Pycnogenol (R) ukwengeza kuthuthukisa ukusebenza kwengqondo, ukunakwa kanye ukusebenza kwengqondo kubafundi. IPanminerva Med. 2011; 53 (3 Suppl 1): 75-82. Buka okungaqondakali.
67. U-Errichi, S., Bottari, A., Belcaro, G., Cesarone, MR, Hosoi, M., Cornelli, U., Dugall, M., Ledda, A., noFeragalli, B. Ukwengeza ngePycnogenol (R) kuthuthukisa izimpawu nezimpawu zokuguquka kokuya esikhathini. IPanminerva Med. 2011; 53 (3 Suppl 1): 65-70. Buka okungaqondakali.
68. Belcaro, G., Luzzi, R., Cesinaro Di, Rocco P., Cesarone, MR, Dugall, M., Feragalli, B., Errichi, BM, Ippolito, E., Grossi, MG, Hosoi, M., Errichi , S., Cornelli, U., Ledda, A., noGizzi, G. Pycnogenol (R) ukuthuthuka ekuphathweni kwesifuba somoya. IPanminerva Med. 2011; 53 (3 Suppl 1): 57-64. Buka okungaqondakali.
69. U-Errichi, BM, Belcaro, G., Hosoi, M., Cesarone, MR, Dugall, M., Feragalli, B., Bavera, P., Hosoi, M., Zulli, C., Corsi, M., Ledda, A., Luzzi, R., noRicci, A. Ukuvimbela i-post thrombotic syndrome nge-Pycnogenol (R) esifundweni sezinyanga eziyishumi nambili. IPanminerva Med. 2011; 53 (3 Suppl 1): 21-27. Buka okungaqondakali.
70. U-Aoki, H., Nagao, J., Ueda, T., Strong, JM, Schonlau, F., Yu-Jing, S., Lu, Y., noHorie, S. Ukuhlolwa kwemitholampilo kwesengezo sePycnogenol (R ) kanye ne-L-arginine ezigulini zaseJapan ezinokungasebenzi kahle okuphakathi kuya kokulingene. I-Phytother.Res. 2012; 26: 204-207. Buka okungaqondakali.
71. U-Ohkita, M., Kiso, Y., noMatsumura, Y. I-Pharmacology ekudleni kwezempilo: ukwenziwa komsebenzi we-vasot endothelial yi-French maritime pine bark extract (Flavangenol). J.Pharmacol.Sci. 2011; 115: 461-465. Buka okungaqondakali.
72. UDvorakova, M., Paduchova, Z., Muchova, J., Durackova, Z., noCollins, A. R. Ngabe i-pycnogenol (R) ikuthonya kanjani ukulimala kwe-oxidative kwi-DNA nekhono layo lokulungisa kubantu asebekhulile? I-Prague.I-Meded. 2010; 111: 263-271. Buka okungaqondakali.
73. UHenrotin, Y., Lambert, C., Couchourel, D., Ripoll, C., noChiotelli, E. Nutraceuticals: ingabe bamelela inkathi entsha ekuphathweni kwe-osteoarthritis? - ukubuyekeza okulandisayo kwezifundo ezithathwe ngemikhiqizo emihlanu. I-Osteoarthritis.Cartilage. 2011; 19: 1-21. Buka okungaqondakali.
74. Pavone, C., Abbadessa, D., Tarantino, M. L., Oxenius, I., Lagana, A., Lupo, A., noRinella, M. [Ukuhlanganisa iSerenoa repens, Urtica dioica nePinus pinaster. Ukuphepha nokusebenza kahle ekwelapheni izimpawu eziphansi zomgudu womchamo. Ucwaningo olulindelekile ezigulini ezingama-320]. I-Urologia. 2010; 77: 43-51. Buka okungaqondakali.
75. UDrieling, R. L., Gardner, C. D., Ma, J., Ahn, D. K., noStafford, R. S. Ayikho imiphumela ezuzisayo yokukhishwa kwegxolo likaphayini ezintweni ezinobungozi besifo senhliziyo. I-Arch.Intern.Med. 9-27-2010; 170: 1541-1547. Buka okungaqondakali.
76. Reuter, J., Wolfle, U., Korting, H. C., noSchempp, C. Yisiphi isitshalo esiphi isifo sesikhumba? Ingxenye 2: Ama-dermatophyte, ukungasebenzi kahle kwama-venous, i-photoprotection, i-actinic keratoses, i-vitiligo, ukulahleka kwezinwele, izinkomba zezimonyo. I-J.Dtsch.Dermatol.Izinsiza. 2010; 8: 866-873. Buka okungaqondakali.
77. Grossi, MG, Belcaro, G., Cesarone, MR, Dugall, M., Hosoi, M., Cacchio, M., Ippolito, E., noBavera, P. Ukwenza ngcono ukugeleza kwama-cochlear ne-Pycnogenol (R) ezigulini ezine tinnitus: ukuhlolwa komshayeli. IPanminerva Med. 2010; 52 (2 Isengezo 1): 63-67. Buka okungaqondakali.
78. Stuard, S., Belcaro, G., Cesarone, MR, Ricci, A., Dugall, M., Cornelli, U., Gizzi, G., Pellegrini, L., noRohdewald, umsebenzi we-PJ Kidney ku-metabolic syndrome kungaba ithuthukiswe ngePycnogenol (R). IPanminerva Med. 2010; 52 (2 Isengezo 1): 27-32. Buka okungaqondakali.
79. UCesarone, uM.R., Belcaro, G., Rohdewald, P., Pellegrini, L., Ledda, A., Vinciguerra, G., Ricci, A., Ippolito, E., Fano, F., Dugall, M., Cacchio, M., Di, Renzo A., Hosoi, M., Stuard, S., noCorsi, M. Ukuthuthukiswa kwezimpawu nezimpawu zokungakwazi ukusebenza kahle kwama-venous kanye ne-microangiopathy ne-Pycnogenol: isifundo esizayo, esilawulwayo. I-Phytomedicine. 2010; 17: 835-839. Buka okungaqondakali.
80. UCesarone, MR, Belcaro, G., Stuard, S., Schonlau, F., Di, Renzo A., Grossi, MG, Dugall, M., Cornelli, U., Cacchio, M., Gizzi, G., no I-Pellegrini, L. Ukugeleza kwezinso nokusebenza komfutho wegazi ophakeme: imiphumela yokuvikela ye-pycnogenol kubahlanganyeli abanomfutho wegazi ophakeme - isifundo esilawulwayo. J.Cardiovasc.Pharmacol.Ther. 2010; 15: 41-46. Buka okungaqondakali.
81. UBelcaro, G., Cesarone, MR, Errichi, B., Di, Renzo A., Grossi, MG, Ricci, A., Dugall, M., Cornelli, U., Cacchio, M., noRohdewald, P. Pycnogenol ukwelashwa kweziqephu ezinzima ze-hemorrhoidal. I-Phytother.Res. 2010; 24: 438-444. Buka okungaqondakali.
82. Steigerwalt, R., Belcaro, G., Cesarone, MR, Di, Renzo A., Grossi, MG, Ricci, A., Dugall, M., Cacchio, M., noSchonlau, F. , nobuhle obubonakalayo ekubonakaleni kwesifo sikashukela kwasekuqaleni. UJ. Ocul. Pharmacol. Okwamanje. U-2009; 25: 537-540. Buka okungaqondakali.
83. UBelcaro, G., Cesarone, M., Silvia, E., Ledda, A., Stuard, S., GV, Dougall, M., Cornelli, U., Hastings, C., noSchonlau, F. Ukusetshenziswa kwansuku zonke I-Reliv Glucaffect amasonto ayi-8 yehlise kakhulu ushukela wegazi nesisindo somzimba ezifundweni ezingama-50. I-Phytother.Res. 4-29-2009; Buka okungaqondakali.
84. URucklidge, J. J., Johnstone, J., noKaplan, B. J. Nutrient izindlela zokwengeza ekwelapheni i-ADHD. Isazi.Umfu. U-2009; 9: 461-476. Buka okungaqondakali.
85. UZibadi, S., Rohdewald, P. J., Park, D., noWatson, R. R.Ukuncishiswa kwezinto ezinobungozi benhliziyo emithanjeni ezifundweni ezinesifo sikashukela sohlobo lwe-2 nge-Pycnogenol supplementation. Ukudla okunomsoco. 2008; 28: 315-320. Buka okungaqondakali.
86. UBelcaro, G., Cesarone, MR, Errichi, S., Zulli, C., Errichi, BM, Vinciguerra, G., Ledda, A., Di Renzo, A., Stuard, S., Dugall, M., Pellegrini , L., Gizzi, G., Ippolito, E., Ricci, A., Cacchio, M., Cipollone, G., Ruffini, I., Fano, F., Hosoi, M., noRohdewald, P. Ukuhluka kuma-protein asebenza ngo-C, ama-radicals wamahhala we-plasma namanani we-fibrinogen ezigulini ezine-osteoarthritis eziphathwe nge-Pycnogenol. I-Redox. 2008; 13: 271-276. Buka okungaqondakali.
87. URyan, J., Croft, K., Mori, T., Wesnes, K., Spong, J., Downey, L., Kure, C., Lloyd, J., noStough, C. Ukuhlolwa kwemiphumela we-antioxidant Pycnogenol ekusebenzeni kwengqondo, iphrofayili ye-serum lipid, i-endocrinological kanye ne-oxidative stress biomarkers kubantu asebekhulile. J I-Psychopharmacol. 2008; 22: 553-562. Buka okungaqondakali.
88. UCisar, P., Jany, R., Waczulikova, I., Sumegova, K., Muchova, J., Vojtassak, J., Durackova, Z., Lisy, M., noRohdewald, P. Umphumela wokukhishwa kwegxolo likaphayini. (Pycnogenol) ngezimpawu zamadolo i-osteoarthritis. I-Phytother.Res. 2008; 22: 1087-1092. Buka okungaqondakali.
89. Suzuki, N., Uebaba, K., Kohama, T., Moniwa, N., Kanayama, N., noKoike, K. Ukukhishwa kwamagxolo ophayini wasolwandle waseFrance kunciphisa kakhulu isidingo semithi ye-analgesic ku-dysmenorrhea: i-multicenter, i-randomized, isifundo esilawulwa izimpumputhe eziphindwe kabili. J Uyazikhukhumeza. 2008; 53: 338-346. Buka okungaqondakali.
90. UBelcaro, G., Cesarone, MR, Errichi, S., Zulli, C., Errichi, BM, Vinciguerra, G., Ledda, A., Di Renzo, A., Stuard, S., Dugall, M., Pellegrini , L., Errichi, S., Gizzi, G., Ippolito, E., Ricci, A., Cacchio, M., Cipollone, G., Ruffini, I., Fano, F., Hosoi, M., no Rohdewald, P. Ukwelashwa kwe-osteoarthritis ne-Pycnogenol. I-SVOS (iSan Valentino Osteo-arthrosis Study). Ukuhlolwa kwezimpawu, izimpawu, ukusebenza komzimba kanye nezici zemithambo yegazi. I-Phytother.Res. 2008; 22: 518-523. Buka okungaqondakali.
91. UDvorakova, M., Jezova, D., Blazicek, P., Trebaticka, J., Skodacek, I., Suba, J., Iveta, W., Rohdewald, P., noDurackova, Z. Ama-catecholamines e-Urinary ezinganeni ezine ukunakekelwa kokushoda kokungasebenzi kahle (ADHD): ukushintshashintsha komzimba ngokukhishwa kwe-polyphenolic kusuka kupine bark (pycnogenol). Umsoco. 2007; 10 (3-4): 151-157. Buka okungaqondakali.
92. UNikolova, V., Stanislavov, R., Vatev, I., Nalbanski, B., noPunevska, M. [Imingcele yesidoda ekungazali kwabesilisa ngemuva kokwelashwa nge-prelox]. IGinekol. (Sofiia) 2007; 46: 7-12. Buka okungaqondakali.
93. UCesarone, MR, Belcaro, G., Rohdewald, P., Pellegrini, L., Ledda, A., Vinciguerra, G., Ricci, A., Gizzi, G., Ippolito, E., Fano, F., Dugall , M., Acerbi, G., Cacchio, M., Di Renzo, A., Hosoi, M., Stuard, S., noCorsi, M. Ukukhululwa ngokushesha kwezimpawu / izimpawu ku-microangiopathy engapheli engapheli ne-pycnogenol: , isifundo esilawulwayo. I-Angiology 2006; 57: 569-576. Buka okungaqondakali.
94. Chovanova, Z., Muchova, J., Sivonova, M., Dvorakova, M., Zitnanova, I., Waczulikova, I., Trebaticka, J., Skodacek, I., noDurackova, Z. Umphumela wokukhishwa kwe-polyphenolic, I-Pycnogenol, esezingeni le-8-oxoguanine ezinganeni ezinenkinga yokunakwa / ukungasebenzi kahle komzimba. I-Radic yamahhala. 2006; 40: 1003-1010. Buka okungaqondakali.
95. UDvorakova, M., Sivonova, M., Trebaticka, J., Skodacek, I., Waczulikova, I., Muchova, J., noDurackova, Z. Umphumela wokukhishwa kwe-polyphenolic kusuka kugxolo lukaphayini, iPycnogenol ezingeni le-glutathione ezinganeni ezihlushwa ukunakekelwa kokushoda kwengqondo (ADHD). I-Redox. 2006; 11: 163-172. Buka okungaqondakali.
96. UVoss, P., Horakova, L., Jakstadt, M., Kiekebusch, D., noGrune, T. Ferritin oxidation nokwehliswa kweproteasomal: ukuvikelwa ngama-antioxidants. I-Radic yamahhala. 2006; 40: 673-683. Buka okungaqondakali.
97. UBelcaro, G., Cesarone, MR, Errichi, BM, Ledda, A., Di, Renzo A., Stuard, S., Dugall, M., Pellegrini, L., Gizzi, G., Rohdewald, P., Ippolito , E., Ricci, A., Cacchio, M., Cipollone, G., Ruffini, I., Fano, F., noHosoi, M. Izilonda zesifo sikashukela: ukuthuthukiswa kwe-microcirculatory kanye nokuphulukiswa okusheshayo nge-pycnogenol. Umtholampilo.Isibhedlela.I-Homost. 2006; 12: 318-323. Buka okungaqondakali.
98. Ahn, J., Grun, I. U., noMustapha, A. Imiphumela yezitshalo ezitshalwayo ekukhuleni kwamagciwane, ukushintsha kombala, kanye ne-lipid oxidation enkomeni ephekiwe. Ukudla Microbiol. 2007; 24: 7-14. Buka okungaqondakali.
99. Grimm, T., Skrabala, R., Chovanova, Z., Muchova, J., Sumegova, K., Liptakova, A., Durackova, Z., noHogger, P. I-single and multiple dose pharmacokinetics ye-maritime pine bark ekhishwe (pycnogenol) ngemuva kokuphathwa ngomlomo kumavolontiya anempilo. BMC.Clin Pharmacol 2006; 6: 4. Buka okungaqondakali.
100. UCesarone, MR, Belcaro, G., Rohdewald, P., Pellegrini, L., Ledda, A., Vinciguerra, G., Ricci, A., Gizzi, G., Ippolito, E., Fano, F., Dugall , M., Acerbi, G., Cacchio, M., Di Renzo, A., Hosoi, M., Stuard, S., noCorsi, M. Ukuqhathaniswa kwePycnogenol neDaflon ekwelapheni ukungasebenzi kahle okungapheli: umuntu ongalindela, olawulwayo funda. Umtholampilo Appl Thromb. 2006; 12: 205-212. Buka okungaqondakali.
101. UTrebaticka, J., Kopasova, S., Hradecna, Z., Cinovsky, K., Skodacek, I., Suba, J., Muchova, J., Zitnanova, I., Waczulikova, I., Rohdewald, P.,. kanye neDurackova, Z. Ukwelashwa kwe-ADHD ngeFrench maritime pine bark extract, Pycnogenol. I-Eur. Ingane Yezingane. I-Psychiatry 2006; 15: 329-335. Buka okungaqondakali.
102. I-Chayasirisobhon, S. Ukusetshenziswa kokukhishwa kwe-pine bark kanye nomkhiqizo wokuhlanganiswa kwamavithamini we-antioxidant njengokwelapha kwe-migraine ezigulini eziphikisayo emithini ye-pharmacologic. Izinwele 2006; 46: 788-793. Buka okungaqondakali.
103. Grimm, T., Chovanova, Z., Muchova, J., Sumegova, K., Liptakova, A., Durackova, Z., noHogger, P. Ukuvinjelwa kokusebenza kweNF-kappaB kanye nokuvalwa kwe-MMP-9 yi-plasma yomuntu amavolontiya ngemuva kokungeniswa kwe-maritime pine bark extract (Pycnogenol). J Inflamm. (ILond) 2006; 3: 1. Buka okungaqondakali.
104. Schafer, A., Chovanova, Z., Muchova, J., Sumegova, K., Liptakova, A., Durackova, Z., noHogger, P. Ukuvinjelwa komsebenzi we-COX-1 nowo-COX-2 yi-plasma yamavolontiya angabantu. ngemuva kokungeniswa kwe-French maritime pine bark extract (Pycnogenol). Biomed.Umakhemikhali. 2006; 60: 5-9. Buka okungaqondakali.
105. UBelcaro, G., Cesarone, MR, Errichi, BM, Ledda, A., Di Renzo, A., Stuard, S., Dugall, M., Pellegrini, L., Rohdewald, P., Ippolito, E., Ricci , A., Cacchio, M., Ruffini, I., Fano, F., noHosoi, M. Izilonda ezinemithambo yegazi: ukuthuthuka okuncishiswa komoya nokululama ngokushesha ngokusetshenziswa kwendawo kwePycnogenol. I-Angiology 2005; 56: 699-705. Buka okungaqondakali.
106. IBaumann, L. Ungakuvimbela kanjani isithombe? J Invest Dermatol. 2005; 125: xii-xiii. Buka okungaqondakali.
107. UTorras, M. A., Faura, C. A., Schonlau, F., noRohdewald, P. Umsebenzi we-Antimicrobial wePycnogenol. I-Phytother Res 2005; 19: 647-648. Buka okungaqondakali.
108. Thornfeldt, C. Ama-Cosmeceuticals aqukethe amakhambi: iqiniso, inganekwane nekusasa. I-Dermatol. Ukuhlinzwa. 2005; 31 (7 Pt 2): 873-880. Buka okungaqondakali.
109. UCesarone, MR, Belcaro, G., Rohdewald, P., Pellegrini, L., Ippolito, E., Scoccianti, M., Ricci, A., Dugall, M., Cacchio, M., Ruffini, I., Fano , F., Acerbi, G., Vinciguerra, MG, Bavera, P., Di Renzo, A., Errichi, BM, noMucci, F. Ukuvimbela i-edema ezindizeni ezinde nePycnogenol. Umtholampilo Appl. Ibhomu. 2005; 11: 289-294. Buka okungaqondakali.
110. U-Huang, W. W., Yang, J. S., Lin, C. F., Ho, W. J., no-Lee, M. R. Pycnogenol kudala umehluko nokwe-apoptosis kumaseli we-promyeloid leukemia HL-60 cells. Leuk. 2005; 29: 685-692. Buka okungaqondakali.
111. USegger, D. noSchonlau, F. Ukwengeza nge-Evelle kuthuthukisa ubushelelezi besikhumba nokunwebeka esifundweni esilawulwa izimpumputhe ezimbili, esilawulwa nge-placebo nabesifazane abangama-62. J Dermatolog. Ukwelapha. 2004; 15: 222-226. Buka okungaqondakali.
112. UMochizuki, M. noHasegawa, N. I-Pycnogenol ivuselela i-lipolysis kumaseli we-3t3-L1 ngokukhuthaza umsebenzi we-beta-receptor mediated. I-Phytother Res 2004; 18: 1029-1030. Buka okungaqondakali.
113. UMochizuki, M. noHasegawa, N. Ukusebenza kokwelapha kwe-pycnogenol ezifweni ezivivinyayo zamathumbu ezivuthayo. I-Phytother Res 2004; 18: 1027-1028. Buka okungaqondakali.
114. UDene, B. A., Maritim, A. C., Sanders, R. A., noWatkins, J. B., III. Imiphumela yokwelashwa kwe-antioxidant emisebenzini ejwayelekile neyesifo sikashukela se-rat retinal enzyme. UJ Ocul. Pharmacol Ther 2005; 21: 28-35. Buka okungaqondakali.
115. Berryman, A. M., Maritim, A. C., Sanders, R. A., noWatkins, J. B., III. Ithonya lokwelashwa kwamagundane esifo sikashukela ngokuhlanganiswa kwe-pycnogenol, i-beta-carotene, ne-alpha-lipoic acid kumingcele yokuxineka kwe-oxidative. UJ Biochem Mol Toxicol 2004; 18: 345-352. Buka okungaqondakali.
116. UNelson, A. B., Lau, B. H., Ide, N., noRong, Y. I-Pycnogenol ivimbela ukuqhuma kwe-macrophage oxidative, i-lipoprotein oxidation, kanye nomonakalo owenziwe yi-DNA onamandla we-hydroxyl. Izidakamizwa Dev. Ind Pharm 1998; 24: 139-144. Buka okungaqondakali.
117. Kim, Y. G. and Park, H. Y. Imiphumela yePycnogenol ekulimaleni kwe-DNA in vitro and expression of superoxide dismutase and HP1 in Escherichia coli SOD and catalase defant cell mutant. I-Phytother.I-2004; 18: 900-905. Buka okungaqondakali.
118. UBelcaro, G., Cesarone, MR, Rohdewald, P., Ricci, A., Ippolito, E., Dugall, M., Griffin, M., Ruffini, I., Acerbi, G., Vinciguerra, MG, Bavera, P., Di Renzo, A., Errichi, BM, noCerritelli, F. Ukuvimbela i-venous thrombosis ne-thrombophlebitis ezindizeni ezihamba isikhathi eside nge-pycnogenol. Umtholampilo Appl. Ibhomu. 2004; 10: 373-377. Buka okungaqondakali.
119. Siler-Marsiglio, K. I., Paiva, M., Madorsky, I., Serrano, Y., Neeley, A., noHeaton, M. B. Izindlela zokuvikela i-pycnogenol kumaseli we-cerebellar granule ahlambalaza i-ethanol. UJ Neurobiol. 2004; 61: 267-276. Buka okungaqondakali.
120. U-Ahn, J., Grun, I. U., noMustapha, A. Imisebenzi elwa namagciwane kanye ne-antioxidant yemikhakha yemvelo ku-vitro nasenkomeni yenkomo. J Ukudla Prot. 2004; 67: 148-155. Buka okungaqondakali.
121. U-Liu, X., Wei, J., Tan, F., Zhou, S., Wurthwein, G., noRohdewald, P. Pycnogenol, ukukhishwa kwegxolo likaphayini lwasolwandle lwaseFrance, kuthuthukisa ukusebenza kwe-endothelial yeziguli ezinomfutho wegazi ophezulu. Impilo Sci 1-2-2004; 74: 855-862. Buka okungaqondakali.
122. UZhang, D., Tao, Y., Gao, J., Zhang, C., Wan, S., Chen, Y., Huang, X., Ilanga, X., uDuan, S., uSchonlau, F., URohdewald, P., noZhao, B. Pycnogenol kuzihlungi zikagwayi zihlasela ama-radicals amahhala futhi zinciphisa i-mutagenicity kanye nobuthi bentuthu kagwayi ku-vivo. I-Toxicol Ind Health 2002; 18: 215-224. Buka okungaqondakali.
123. IMaritim, A., Dene, B. A., Sanders, R. A., kanye neWatkins, J. B., III. Imiphumela yokwelashwa kwe-pycnogenol ekucindezelekeni kwe-oxidative kumagundane esifo sikashukela esenziwe yi-streptozotocin. J I-Biochem Mol Toxicol 2003; 17: 193-199. Buka okungaqondakali.
124. UHosseini, S., Pishnamazi, S., Sadrzadeh, S. M., Farid, F., Farid, R., noWatson, R. R. Pycnogenol ((R)) ku-Management of Asthma. J Med Ukudla 2001; 4: 201-209. Buka okungaqondakali.
125. USharma, S. C., Sharma, S., noGulati, O. P. Pycnogenol uvimbela ukukhishwa kwe-histamine kumaseli amangqamuzana. I-Phytother Res 2003; 17: 66-69. Buka okungaqondakali.
126. UDevaraj, S., Vega-Lopez, S., Kaul, N., Schonlau, F., Rohdewald, P., noJialal, I. Ukwengeza ngegxolo likaphayini elikhishwe ku-polyphenols kwandisa amandla e-plasma antioxidant futhi kuguqula i-plasma lipoprotein Iphrofayili. I-Lipids 2002; 37: 931-934. Buka okungaqondakali.
127. URoseff, S. J. Ukwenza ngcono ikhwalithi yesidoda nokusebenza nge-French maritime pine tree bark extract. UJ Reprod Med 2002; 47: 821-824. Buka okungaqondakali.
128. Ni, Z., Mu, Y., noGulati, O. Ukwelashwa kwe-melasma ne-Pycnogenol. I-Phytother.Res. 2002; 16: 567-571. Buka okungaqondakali.
129. UKimbrough, C., Chun, M., dela, Roca G., noLau, B. H. PYCNOGENOL ukuhlafuna ushingamu kunciphisa ukopha kwe-gingival nokwakhiwa kwamacwecwe. I-Phytomedicine 2002; 9: 410-413. Buka okungaqondakali.
130. UPeng, Q. L., Buz'Zard, A. R., noLau, B. H. Pycnogenol ivikela ama-neurons kwi-apoptosis eyenziwe nge-amyloid-beta peptide. I-Brain Res Mol Brain Res 7-15-2002; 104: 55-65. Buka okungaqondakali.
131. UCho, K. J., Yun, C. H., Packer, L., noChung, A. S. Izindlela zokuvimbela ama-bioflavonoids akhishwe kugxolo lukaPinus maritima lapho kushiwo ama-cytokines anamandla okuvuvukala. U-Ann N Y Acad Sci 2001; 928: 141-156. Buka okungaqondakali.
132. UKim, H. C. noHealey, J. M. Imiphumela yokukhishwa kwegxolo likaphayini elenzelwa amagundane amadala angenwe yigciwane le-Cryptosporidium parvum. U-Am J Chin Med 2001; 29 (3-4): 469-475. Buka okungaqondakali.
133. UStefanescu, M., Matache, C., Onu, A., Tanaseanu, S., Dragomir, C., Constantinescu, I., Schonlau, F., Rohdewald, P., noSzegli, G.Ukusebenza ngempumelelo ekwelashweni weziguli ze-systemic lupus erythematosus. I-Phytother Res 2001; 15: 698-704. Buka okungaqondakali.
134. Cho, KJ, Yun, CH, Yoon, DY, Cho, YS, Rimbach, G., Packer, L., noChung, AS Umphumela wama-bioflavonoids akhishwe kugxolo lukaPinus maritima kukhiqiza i-cytokine interleukin-1 ekukhiqizeni i-lipopolysaccharide- kukhuthazwe i-RAW 264.7. I-Toxicol Appl. Pharmacol 10-1-2000; 168: 64-71. Buka okungaqondakali.
135. UHuynh, H. T. noTeel, R. W. Ukungeniswa okukhethiwe kwe-apoptosis kumaseli womdlavuza womuntu wesifuba (MCF-7) yi-pycnogenol. I-Anticancer Res 2000; 20: 2417-2420. Buka okungaqondakali.
136. UPeng, Q., Wei, Z., noLau, B. H. Pycnogenol unqanda i-tumor necrosis factor-alpha eyenziwe nge-nuclear factor kappa B activation kanye ne-adhesion molecule expression in human vascular endothelial cells. Iseli Mol Life Sci 2000; 57: 834-841. Buka okungaqondakali.
137. I-Araghi-Niknam, M., Hosseini, S., Larson, D., Rohdewald, P., noWatson, R. R. Ukukhishwa kwegxolo le-Pine kunciphisa ukuhlanganiswa kweplatelet. Ihlanganisiwe. 3-21-2000; 2: 73-77. Buka okungaqondakali.
138. UMoini, H., Arroyo, A., Vaya, J., noPacker, L.Imiphumela ye-Bioflavonoid ku-mitochondrial yokuphefumula i-electron transport chain kanye ne-cytochrome c redox state. I-Redox. I-1999; 4 (1-2): 35-41. Buka okungaqondakali.
139. I-Bors, W., Michel, C., ne-Stettmaier, K. izifundo ze-elektroni ye-paramagnetic resonance yezinhlobo ezinamandla zama-proanthocyanidins nama-gallate esters. I-Arch Biochem Biophys. 2-15-2000; 374: 347-355. Buka okungaqondakali.
140. UKobayashi, M. S., Han, D., noPacker, L. Antioxidants kanye nokukhishwa kwamakhambi kuvikela amaseli we-HT-4 neuronal ngokumelene ne-cytotoxicity eyenziwe nge-glutamate. I-Radic yamahhala. 2000; 32: 115-124. Buka okungaqondakali.
141. IHasegawa, N. Ukukhuthazwa kwe-lipolysis yi-pycnogenol. I-Phytother Res 1999; 13: 619-620. Buka okungaqondakali.
142. UPacker, L., Rimbach, G., noVirgili, F. Umsebenzi we-Antioxidant nezakhiwo ze-biologic yomkhiqizo ocebile we-procyanidin ovela kugxolo likaphayini (Pinus maritima), i-pycnogenol. I-Radic yamahhala. Biol Med 1999; 27 (5-6): 704-724. Buka okungaqondakali.
143. UHuynh, H. T. noTeel, R. W. Imiphumela ye-Pragnogenol elawulwa nge-intragastrically ku-NNK metabolism kumagundane e-F344. I-Anticancer Res 1999; 19 (3A): 2095-2099. Buka okungaqondakali.
144. UHuynh, H. T. noTeel, R. W. Imiphumela ye-pycnogenol kwi-microsomal metabolism ye-nitrosamine NNK eqondene nogwayi njengomsebenzi wobudala. ICancer Lett 10-23-1998; 132 (1-2): 135-139. Buka okungaqondakali.
145. Belcaro, G., Cesarone, MR, Dugall, M., Hosoi, M., Ippolito, E., Bavera, P., noGrossi, Ukuphenywa kweMG kwePycnogenol (R) kuhlangene necoenzymeQ10 ezigulini zokuhluleka kwenhliziyo (NYHA II / III). IPanminerva Med 2010; 52 (2 Suppl 1): 21-25. Buka okungaqondakali.
146. UClark, uC. E., u-Arnold, u-E, uLasserson, u-T.J, no-Wu, u-T.Ukungenelela kwamakhambi kwe-asthma engapheli kubantu abadala nasezinganeni: ukubuyekezwa okuhlelekile nokuhlaziywa kwe-meta. UPrim.Care Respir. J 2010; 19: 307-314. Buka okungaqondakali.
147. Steigerwalt, R. D., Gianni, B., Paolo, M., Bombardelli, E., Burki, C., noSchonlau, F. Imiphumela ye-Mirtogenol ekuhambeni kwegazi ocular kanye nomfutho wegazi ophezulu we-intraocular ezifundweni ezingenasifo. IMol Vis 2008; 14: 1288-1292. Buka okungaqondakali.
148. ULedda, A., Belcaro, G., Cesarone, MR, Dugall, M., noSchonlau, F. Ukuphenywa kwesitshalo esiyinkimbinkimbi sokukhipha ukungasebenzi kahle kwe-erectile okungahleliwe, okulawulwa kabili, okulawulwa yi-placebo, okufana- ukutadisha ingalo. BJU.Int. 2010; 106: 1030-1033. Buka okungaqondakali.
149. UStanislavov, R., uNikolova, V., noRohdewald, P. Ukuthuthukiswa kwamapharamitha wesemini ngePlox: icala elilawulwa ngokungahleliwe, eliyimpumputhe, elilawulwa nge-placebo. I-Phytother.I-2009; 23: 297-302. Buka okungaqondakali.
150. UWilson D, uEvans M, uGuthrie N et al. Ucwaningo lokuhlola olulawulwa ngokungahleliwe, oluyimpumputhe, olulawulwa yi-placebo ukuhlola amandla we-pycnogenol wokuthuthukisa izimpawu ze-allergen rhinitis. I-Phytother Res 2010; 24: 1115-9. Buka okungaqondakali.
151. UBelcaro G, uCesarone MR, uRicci A, et al. Ukulawulwa kwe-edema ezifundweni ezinomfutho wegazi ophathwe nge-calcium antagonist (nifedipine) noma i-angiotensin-converting enzyme inhibitors nge-pycnogenol. Umtholampilo Appl Thromb Hemost 2006; 12: 440-4. Buka okungaqondakali.
152. UVinciguerra G, uBelcaro G, uCesarone MR, et al. Amajaqamba nobuhlungu bemisipha: ukuvimbela ngePyconogenol ezifundweni ezijwayelekile, iziguli ezinemithambo yegazi, abagijimi, ama-claudicants kanye ne-microangiopathy yesifo sikashukela. I-Angiology 2006; 57: 331-9. Buka okungaqondakali.
153. UCesarone MR, uBelcaro G, uRohdewald P, et al. Ukwenza ngcono i-microangiopathy yesifo sikashukela ne-Pycnogenol: Ucwaningo oluzokwenzeka, olulawulwayo I-Angiology 2006; 57: 431-6. Buka okungaqondakali.
154. U-Liu X, Wei J, Tan F, et al. Umphumela we-Antidiabetic wePycnogenol French maritime pine bark ekhishwa ezigulini ezinesifo sikashukela sohlobo II. Impilo Sci 2004; 75: 2505-13. Buka okungaqondakali.
155. U-Liu X, uZhou HJ, uRohdewald P.Amagxolo ase-French maritime pine bark akhipha i-pycnogenol dose-encike kwehlisa i-glucose kuhlobo lwe-2 lweziguli zikashukela (incwadi). Ukunakekelwa yisifo sikashukela 2004; 27: 839. Buka okungaqondakali.
156. UKohama T, uSuzuki N, u-Ohno S, u-Inoue M. Ukusebenza kahle kwe-French maritime pine bark ekhishwe ku-dysmenorrhea: isilingo esivulekile somtholampilo. UJ Reprod Med 2004; 49: 828-32. Buka okungaqondakali.
157. UKohama T, Inoue M. Pycnogenol unciphisa izinhlungu ezihambisana nokukhulelwa. I-Phytother Res 2006; 20: 232-4. Buka okungaqondakali.
158. UBlazso G, uGabor M, uSchonlau F, uRohdewald P. Pycnogenol usheshisa ukwelashwa kwesilonda futhi wehlise ukwakheka kwesibazi. I-Phytother Res 2004; 18: 579-81. Buka okungaqondakali.
159. UYang HM, uLiao MF, uZhu SY, et al. Isivivinyo esilawulwa ngokungahleliwe, esiyimpumputhe, esilawulwa yi-placebo ngomphumela wePycnogenol ku-climacteric syndrome kwabesifazane be-peri-menopausal. I-Acta Obstet Gynecol Scand 2007; 86: 978-85. Buka okungaqondakali.
160. ULau BH, uRiesen SK, uTruong KP, et al. I-Pycnogenol njengenhlanganisela ekuphathweni kwesifuba somoya sobuntwana. J Isifuba Somoya 2004; 41: 825-32. Buka okungaqondakali.
161. UCesarone MR, uBelcaro G, uNicolaides AN, et al. Ukuvimbela i-venous thrombosis ezindizeni ezihamba isikhathi eside ngamaFlite Tabs: Isivivinyo esilawulwa ngokungahleliwe, esilawulwa yi-LONFLIT-FLITE. I-Angiology 2003; 54: 531-9. Buka okungaqondakali.
162. UDurackova Z, uTrebaticky B, uNovotny V, et al. I-Lipid metabolism kanye nokwenza ngcono ukusebenza kwe-Pycnogenol, kukhishwe kumagxolo ePinus pinaster ezigulini ezinenkinga yokungasebenzi kahle kwe-erectile-isifundo somshayeli. INutr Res 2003; 23: 1189-98 ..
163. UStanislavov R, uNikolova V. Ukwelashwa kokungasebenzi kahle kwe-erectile nge-pycnogenol ne-L-arginine. J Ubulili Bomshado Ther 2003; 29: 207-13 .. Buka okungaqondakali.
164. UHosseini S, Lee J, Sepulveda RT, et al. Ucwaningo olwenziwe ngokungahleliwe, oluyimpumputhe, olulawulwa yi-placebo, olulindelekile, oluzothathwa ngesonto eli-16 ukuthola indima ye-pycnogenol ekuguquleni umfutho wegazi ezigulini ezinomfutho wegazi ophansi. I-Nut Res 2001; 21: 1251-60.
165. I-Bito T, i-Roy S, i-Sen CK, i-Packer L. I-Pine bark ikhipha i-pycnogenol yehlisela phansi ukunamathela okwenziwe nge-IFN-gamma kwamaseli we-T kuma-keratinocyte womuntu ngokuvimbela ukubonakaliswa kwe-ICAM-1 okungafakwanga. I-Radic Biol Med yamahhala 2000; 28: 219-27 .. Buka okungaqondakali.
166. UVirgili F, uPagana G, uBourne L, et al. Ukukhishwa kwe-asidi i-Ferulic njengophawu lokusetshenziswa kukakhonkolo waseFrance wasolwandle (uPinus maritima). I-Radic Biol Med yamahhala 2000; 28: 1249-56 .. Buka okungaqondakali.
167. I-Tenenbaum S, i-Paull JC, i-Sparrow EP, et al. Ukuqhathanisa kokuhlola kwePycnogenol ne-methylphenidate kubantu abadala abane-Attention-Deficit / Hyperactivity Disorder (ADHD). J Atten Disord 2002; 6: 49-60 .. Buka okungaqondakali.
168. IHasegawa N. Ukuvinjelwa kwe-lipogenesis yi-pycnogenol. I-Phytother Res 2000; 14: 472-3. Buka okungaqondakali.
169. Liu F, Lau BHS, Peng Q, Shah V. I-Pycnogenol ivikela amaseli endothelial e-vascular ekulimaleni okubangelwa yi-beta-amyloid. IBiol Pharm Bull 2000; 23: 735-7. Buka okungaqondakali.
170. I-Virgili F, i-Kim D, i-Packer L.Procyanidins ekhishwe ku-pine bark ivikela i-alpha-tocopherol kuma-ECV 304 endothelial cell aphonswe inselelo yi-RAW 264.7 macrophages: indima ye-nitric oxide ne-peroxynitrite. Izincwadi ze-FEBS 1998; 431: 315-8. Buka okungaqondakali.
171. IPark YC, uRimbach G, uSaliou C, et al. Umsebenzi wama-flavonoid we-monomeric, dimeric, ne-trimeric ku-NO production, i-TNF-alpha secretion, kanye ne-NF-KB-expression expression of gene expression in RAW 264.7 macrophages. Izincwadi ze-FEBS 2000: 465; 93-7. Buka okungaqondakali.
172. USaliou C, Rimbach G, Molni H, McLaughlin L, Hosseini S, Lee J, et al. I-erythema eyenziwe nge-solar ultraviolet esikhumbeni somuntu kanye nenkulumo ye-nuclear factor-kappa-b-dependence expression in keratinocytes is modulated by a French Maritime pine bark extract. I-Radic Biol Med yamahhala ngo-2001; 30: 154-60. Buka okungaqondakali.
173. UCheshier JE, u-Ardestani-Kaboudanian S, uLiang B, et al. Ukuzivikela kwamagciwane nge-pycnogenol kumagundane afakwe i-retrovirus noma e-ethanol. Impilo Sci 1996; 58: 87-96. Buka okungaqondakali.
174. UJialal I, uDevaraj S, uHirany S, et al. Umphumela we-pycnogenol supplementation kuzimpawu zokuvuvukala. Ezinye izindlela zokwelapha 2001; 7: S17.
175. I-Koch R. Ucwaningo lokuqhathanisa i-venostatin ne-pycnogenol ekungeneni okungapheli kwama-venous. I-Phytother Res 2002: 16: S1-S5. I-Phytother Res 2002: 16: S1-S5. Buka okungaqondakali.
176. UHeiman SW. IPycnogenol ye-ADHD? J I-Acad Ingane Yentsha Yengane Yezingane I-Psychiatry 1999; 38: 357-8. Buka okungaqondakali.
177. I-Ohnishi ST, i-Ohnishi T, i-Ogunmola GB. I-Sickle cell anemia: indlela yokudla okunempilo yesifo samangqamuzana. Ukudla okunomsoco 2000; 16: 330-8. Buka okungaqondakali.
178. IMensink RP, uKatan MB. Ucwaningo lwezifo kanye nokuhlola ngomphumela wamafutha omnqumo ku-serum ephelele ne-HDL cholesterol kumavolontiya anempilo. I-Eur J Clin Nutrit 1989; 43 Suppl 2: 43-8. Buka okungaqondakali.
179. UPutter M, uGrotemeyer KH, uWurthwein G, et al. Ukuvinjelwa kokuhlanganiswa kweplatelet okubangelwa ukubhema yi-aspirin ne-pycnogenol. IThromb Res 1999; 95: 155-61. Buka okungaqondakali.
180. UDauer A, uMetzner P, uSchimmer O.Proanthocyanidins ovela kumagxolo kaHamamelis virginiana akhombisa izakhiwo ze-antimutagenic ezilwa namakhemikhali e-nitroaromatic. UPlanta Med 1998; 64: 324-7. Buka okungaqondakali.
181. I-Fitzpatrick DF, i-Bing, i-Rohdewald P. Endothelium imiphumela yemithambo encike kuPycnogenol. UJ Cardiovasc Pharmacol 1998; 32: 509-15. Buka okungaqondakali.
182. U-Liu FJ, uZhang YX, uLau BH. I-Pycnogenol ithuthukisa imisebenzi yokuzivikela emzimbeni kanye ne-haemopoietic kumagundane asheshisa i-senescence. Iseli Mol Life Sci 1998; 54: 1168-72. Buka okungaqondakali.
183. UTixier JM, et al. Ubufakazi obenziwe nge-vivo kanye ne-in vitro izifundo ezibopha ama-pycnogenols ku-elastin zithinta izinga lazo lokwehla kwama-elastases. I-Biochem Pharmacol 1984; 33: 3933-9. Buka okungaqondakali.
184. URoseff SJ, uGulati R. Ukwenza ngcono ikhwalithi yesidoda yi-pycnogenol. I-Eur Bull Drug Res 1999; 7: 33-6.
185. UKohama T, uSuzuki N. Ukwelashwa kokuphazamiseka kwezifo zabesifazane nge-pycnogenol. I-Eur Bull Drug Res 1999; 7: 30-2.
186. I-Pavlovic P. Ukukhuthazela okuthuthukile ngokusebenzisa ama-antioxidants. I-Eur Bull Drug Res 1999; 7: 26-9.
187. UWang S, uTan D, uZhao Y, et al. Umphumela we-pycnogenol ku-microcirculation, iplatelet function kanye ne-ischemic myocardium ezigulini ezinezifo zomthambo we-coronary. I-Eur Bull Drug Res 1999; 7: 19-25.
188. URohdewald P. Ukunciphisa ubungozi bokushaywa unhlangothi nokushaya kwenhliziyo nge-pycnogenol. I-Eur Bull Drug Res 1999; 7: 14-18.
189. IGulati OP. I-Pycnogenol ezinkingeni ze-venous: isibuyekezo. I-Eur Bull Drug Res 1999; 7: 8-13.
190. URohdewald P. Bioavailability kanye ne-metabolism ye-pycnogenol. I-Eur Bull Drug Res 1999; 7: 5-7.
191. UWatson RR. Ukuncishiswa kwezici ezinobungozi besifo senhliziyo ngemfucumfucu yolwandle yaseFrance. I-CVR & R 1999; Juni: 326-9.
192. I-Spadea L, i-Balestrazzi E. Ukwelashwa kwama-retinopathies e-vascular nge-pycnogenol. I-Phytother Res 2001; 15: 219-23. Buka okungaqondakali.
193. I-Schmidtke I, iSchoop W. Pycnogenol: i-stasis edema kanye nokwelashwa kwayo. ISchweizerische Zeitschrift fur GanzheitsMedizin 1995; 3: 114-5.
194. I-Petrassi C, i-Mastromarino A, i-Spartera C. I-Pycnogenol ekungazini kahle okungapheli. I-Phytomedicine 2000; 7: 383-8. Buka okungaqondakali.
195. I-Arcangeli P. Pycnogenol ekungeneni kahle okungapheli kwama-venous. UFitoterapia 2000; 71: 236-44. Buka okungaqondakali.
196. I-Rice-Evans CA, i-Packer L, ama-eds. Ama-Flavonoids Kwezempilo Nezifo. IManhattan, NY: UMarcel Dekker, Inc., 1998.
197. Iphakethe L, Midori H, Toshikazu Y, eds. Izithako zokudla ze-Antioxidant kwezempilo yabantu. ISan Diego: I-Academic Press, ngo-1999.
198. I-Grosse Duweler K, i-Rohdewald P.I-metabolites ye-Urinary ye-French maritime pine bark ekhishwe kubantu. I-Pharmazie 2000; 55: 364-8. Buka okungaqondakali.
199. UFoster S, uTyler VE. I-Herbal Honest Herbal, ka-4, Binghamton, NY: I-Haworth Herbal Press, ngo-1999.
200. USkyrme-Jones RA, O'Brien RC, uBerry KL, uMeredith IT. Ukwengeza i-Vitamin E kuthuthukisa ukusebenza kwe-endothelial kuhlobo I sikashukela mellitus: isifundo esilawulwa ngokungahleliwe, esilawulwa yi-placebo. UJ Am Coll Cardiol 2000; 36: 94-102. Buka okungaqondakali.
201. Izinkinga ze-Coagulation eziphathelene novithamini E. Am J Pediatr Hematol Oncol 1979; 1: 169-73. Buka okungaqondakali.
202. I-Branchey L, i-Branchey M, i-Shaw S, i-Lieber CS. Ubudlelwano phakathi kwezinguquko kuma-plasma amino acid nokudangala ezigulini ezidakayo. NginguJ J Psychiatry 1984; 141: 1212-5. Buka okungaqondakali.
203. Isikhungo Sezokwelapha. Indima yamaprotheni nama-amino acid ekusekeleni nasekuthuthukiseni ukusebenza. IWashington, DC: National Academy Press, 1999. Itholakala ku: http://books.nap.edu/books/0309063469/html/309.html#pagetop
204. INewall CA, Anderson LA, uPhilpson JD. Herbal Medicine: Umhlahlandlela Wongoti Bezempilo. ILondon, e-UK: I-Pharmaceutical Press, ngo-1996.
205. UTyler VE. Amakhambi Okuzikhethela. IBinghamton, NY: Imikhiqizo Yemikhiqizo Yezokwelapha, 1994.
206. UBlumenthal M, u-ed. I-Complete German Commission E Monographs: Umhlahlandlela Wezokwelapha Emithini Yemithi. I-Trans. S. Klein. IBoston, MA: Umkhandlu Wezamabhodlela waseMelika, ngo-1998.

Kugcine ukubuyekezwa - 10/02/2020